Terns Pharmaceuticals Management
Management criteria checks 2/4
Terns Pharmaceuticals' CEO is Senthil Sundaram, appointed in Jul 2020, has a tenure of 2.33 years. total yearly compensation is $3.13M, comprised of 16.4% salary and 83.6% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth €36.68K. The average tenure of the management team and the board of directors is 2 years and 1.9 years respectively.
Key information
Senthil Sundaram
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 16.4% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$59m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$3m | US$514k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$34m |
| Dec 31 2020 | US$14m | US$208k | -US$29m |
Compensation vs Market: Senthil's total compensation ($USD3.13M) is above average for companies of similar size in the German market ($USD603.52K).
Compensation vs Earnings: Senthil's compensation has been consistent with company performance over the past year.
CEO
Senthil Sundaram (44 yo)
2.3yrs
Tenure
US$3,126,295
Compensation
Mr. Senthil Vel Sundaram serves as Independent Director at Social Capital Suvretta Holdings Corp. I since September 24, 2021. He has been Chief Executive Officer and Director of Terns Pharmaceuticals, Inc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.13m | 0.020% $ 36.7k | |
| President & Head of Research & Development | 2.4yrs | US$1.69m | 0% $ 0 | |
| COO, General Counsel & Secretary | 2yrs | US$1.48m | 0.020% $ 36.7k | |
| Co-Founder & Executive Officer | no data | no data | 0.76% $ 1.4m | |
| CFO & Treasurer | 2.3yrs | US$3.46m | 0.020% $ 36.7k | |
| Senior VP & Head of Research | less than a year | no data | no data | |
| Senior VP & Chief Development Officer | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
2.0yrs
Average Tenure
44yo
Average Age
Experienced Management: 430's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.13m | 0.020% $ 36.7k | |
| Independent Director | 4.1yrs | US$365.54k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$196.91k | 0% $ 0 | |
| Independent Director | 2.6yrs | US$373.33k | 0% $ 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Chairman | 1.9yrs | US$220.29k | 0% $ 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Member of Scientific Advisor | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 1.9yrs | US$198.29k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$320.09k | no data |
1.9yrs
Average Tenure
53.5yo
Average Age
Experienced Board: 430's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.